The association of SMAD7 polymorphisms with colorectal cancer susceptibility and clinicopathological features in the Iranian population
Gastroenterology and Hepatology from Bed to Bench,
Vol. 13 No. 1 (2020),
22 January 2020
,
Page 23-30
https://doi.org/10.22037/ghfbb.v13i1.1721
Abstract
Background: Genome-wide association studies (GWAS) have identified 18q21 as a risk locus for colorectal cancer (CRC), which maps to the SMAD7 gene. Our aim was to investigate the association between two single nucleotide polymorphisms (SNPs) of SMAD7 and the risk of CRC in the Iranian individuals.
Methods: This case–control study was conducted on 109 CRC cases and 109 controls in the Iranian population to evaluate the influence of two SNPs of SMAD7, rs2337106 and rs6507874, on the risk of CRC as well as on clinicopathological features. Genotype determination was performed by TaqMan assay via an ABI 7500 Real Time PCR System (Applied Biosystems) for DNA of peripheral blood. Descriptive analysis and logistic regression model were used for statistical analyses.
Results: Genotyping of the SNPs in the SMAD7 gene showed that the frequency of G allele of rs2337106 was 53.7% in controls and 56.4% in cases (p-value=0.564) and the frequency of C allele of rs6507874 was 55.5% in controls and 56.3% in cases (p-value=0.772). Besides, there were no significant differences in genotype frequencies of these SNPs between CRC patients and controls. The SMAD7 genotypes were also not associated with the risk of CRC as well as with any clinicopathological characteristics such as tumor site, tumor grade and stage TNM in CRC patients (p-value>0.05), even after adjustment for sex, age and smoking status.
Conclusion: Our results provided the first evidence that SMAD7 genotypes, rs2337106 and rs6507874, could not be predisposing markers in genetic susceptibility to CRC in an Iranian population, at least in the studied population.
- SMAD7
- single nucleotide polymorphism
- colorectal cancer
How to Cite
References
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: a cancer journal for clinicians 2011; 61(2):69-90.
Sung JJ, Lau JY, Young GP, Sano Y, Chiu H, Byeon J, et al. Asia Pacific consensus recommendations for colorectal cancer screening. Gut 2008; 57(8):1166-1176.
Byeon J-S, Yang S-K, Kim TI, Kim WH, Lau JY, Leung W-K, et al. Colorectal neoplasm in asymptomatic Asians: a prospective multinational multicenter colonoscopy survey. Gastrointestinal endoscopy 2007; 65(7):1015-1022.
Azadeh S, Moghimi-Dehkordi B, Fatem S, Pourhoseingholi M, Ghiasi S, Zali M. Colorectal cancer in Iran: an epidemiological study. Asian Pacific journal of cancer prevention: APJCP 2008; 9(1):123-126.
Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. European journal of cancer 2006; 42(2):216-227.
Lichtenstein P, Holm NV, Verkasalo PK, Iliadou A, Kaprio J, Koskenvuo M, et al. Environmental and heritable factors in the causation of cancer—analyses of cohorts of twins from Sweden, Denmark, and Finland. New England journal of medicine 2000; 343(2):78-85.
Stolfi C, Marafini I, De Simone V, Pallone F, Monteleone G.The dual role of Smad7 in the control of cancer growth and metastasis. International journal of molecular sciences 2013; 14(12):23774-23790.
Massagué J. TGFβ in cancer. Cell 2008; 134(2):215-230.
Roberts AB, Wakefield LM. The two faces of transforming growth factor β in carcinogenesis. Proceedings of the National Academy of Sciences 2003; 100(15):8621-8623.
Nakao A, Afrakhte M, Morn A, Nakayama T, Christian JL, Heuchel R, et al. Identification of Smad7, a TGFβ-inducible antagonist of TGF-β signalling. Nature 1997; 389(6651):631.
Zhang S, Fei T, Zhang L, Zhang R, Chen F, Ning Y,et al. Smad7 antagonizes transforming growth factor β signaling in the nucleus by interfering with functional Smad-DNA complex formation. Molecular and cellular biology 2007; 27(12):4488-4499.
Hayashi H, Abdollah S, Qiu Y, Cai J, Xu Y-Y, Grinnell BW,et al. The MAD-related protein Smad7 associates with the TGFβ receptor and functions as an antagonist of TGFβ signaling. Cell 1997; 89(7):1165-1173.
Yan X, Liu Z, Chen Y. Regulation of TGF-β signaling by Smad7. Acta biochimica et biophysica Sinica 2009; 41(4):263-272.
Huang Y, Wu W, Nie M, Li C, Wang L. SMAD7 polymorphisms and colorectal cancer risk: a meta-analysis of case-control studies. Oncotarget 2016; 7(46):75561.
Broderick P, Carvajal-Carmona L, Pittman AM, Webb E, Howarth K, Rowan A, et al. A genome-wide association study shows that common alleles of SMAD7 influence colorectal cancer risk. Nature genetics 2007; 39(11):1315.
Tenesa A, Farrington SM, Prendergast JG, Porteous ME, Walker M, Haq N, et al. Genome-wide association scan identifies a colorectal cancer susceptibility locus on 11q23 and replicates risk loci at 8q24 and 18q21. Nature genetics 2008; 40(5):631.
Fortini BK, Tring S, Plummer SJ, Edlund CK, Moreno V, Bresalier RS, et al. Multiple functional risk variants in a SMAD7 enhancer implicate a colorectal cancer risk haplotype. PloS one 2014; 9(11):e111914.
Grau AM, Datta PK, Zi J, Halder SK, Beauchamp RD. Role of Smad proteins in the regulation of NF-κB by TGF-β in colon cancer cells. Cellular signalling 2006; 18(7):1041-1050.
Halder SK, Rachakonda G, Deane N, Datta P. Smad7 induces hepatic metastasis in colorectal cancer. British journal of cancer 2008; 99(6):957.
Luo L, Li N, Lv N, Huang D. SMAD7: a timer of tumor progression targeting TGF-β signaling. Tumor Biology 2014; 35(9):8379-8385.
Kleeff J, Ishiwata T, Maruyama H, Friess H, Truong P, Büchler M,et al. The TGF-β signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. Oncogene 1999; 18(39):5363.
Boulay JL, Mild G, Reuter J, Lagrange M, Terracciano L, Lowy A,et al. Combined copy status of 18q21 genes in colorectal cancer shows frequent retention of SMAD7. Genes, Chromosomes and Cancer 2001; 31(3):240-247.
Briones-Orta MA, Tecalco-Cruz AC, Sosa-Garrocho M, Caligaris C, Macias-Silva M. Inhibitory Smad7: emerging roles in health and disease. Current molecular pharmacology 2011; 4(2):141-153.
Boulay JL, Mild G, Lowy A, Reuter J, Lagrange M, Terracciano L,et al. SMAD7 is a prognostic marker in patients with colorectal cancer. International journal of cancer 2003; 104(4):446-449.
Halder SK, Beauchamp RD, Datta PK. Smad7 induces tumorigenicity by blocking TGF-beta-induced growth inhibition and apoptosis. Experimental cell research 2005; 307(1):231-246.
Rizzo A, Waldner MJ, Stolfi C, Sarra M, Fina D, Becker C, et al. Smad7 expression in T cells prevents colitis-associated cancer. Cancer Res 2011; 71(24):7423-7432.
Zhang C, Li X, Fu W, Wang Y, Wang T, Wang W, et al. SMAD7 rs4939827 variant contributes to colorectal cancer risk in Chinese population. Oncotarget 2017; 8(25):41125-41131.
Slattery ML, Herrick J, Curtin K, Samowitz W, Wolff RK, Caan BJ, et al. Increased risk of colon cancer associated with a genetic polymorphism of SMAD7. Cancer Res 2010; 70(4):1479-1485.
Jiang X, Castelao JE, Vandenberg D, Carracedo A, Redondo CM, Conti DV, et al. Genetic variations in SMAD7 are associated with colorectal cancer risk in the colon cancer family registry. PLoS One 2013; 8(4):e60464.
Pittman AM, Naranjo S, Webb E, Broderick P, Lips EH, van Wezel T, et al. The colorectal cancer risk at 18q21 is caused by a novel variant altering SMAD7 expression. Genome Res 2009; 19(6):987-993.
Mates IN, Jinga V, Csiki IE, Mates D, Dinu D, Constantin A, et al. Single nucleotide polymorphisms in colorectal cancer: associations with tumor site and TNM stage. Journal of gastrointestinal and liver diseases : JGLD 2012; 21(1):45-52.
- Abstract Viewed: 123 times
- PDF Downloaded: 92 times